Protagenic Therapeutics (PTIX)

Executive Summary

Protagenic Therapeutics is a New York-based biotech developing first-in-class neuropeptide therapeutics targeting the brain's stress response system for stress-related disorders such as depression, anxiety, PTSD, and addiction. Founded in 2015, the company is in early stages with no approved products or disclosed pipeline details. Its lead candidate is believed to be a neuropeptide analog modulating the corticotropin-releasing factor (CRF) pathway. The company's small market cap (~$1M) and limited public information suggest a high-risk, early-stage profile. Recent advancements may include preclinical data generation and IND-enabling studies. The path to value inflection hinges on successful clinical translation of its platform, with potential catalysts including trial initiations or licensing deals. Given the lack of disclosed milestones and high competitive landscape in neuropsychiatry, conviction is low.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 trial initiation for lead neuropeptide candidate (PT001)30% success
• Q3 2026Presentation of preclinical efficacy data at a major neuroscience conference (e.g., Society for Neuroscience)50% success
• H2 2026Announcement of strategic partnership or licensing agreement for platform technology25% success